124 related articles for article (PubMed ID: 38407967)
21. Utility of mutational analysis for risk stratification of indeterminate thyroid nodules in a real-world setting.
Torrecillas V; Sharma A; Neuberger K; Abraham D
Clin Endocrinol (Oxf); 2022 Apr; 96(4):637-645. PubMed ID: 34605038
[TBL] [Abstract][Full Text] [Related]
22. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
Witt RL
Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology.
Valderrabano P; Khazai L; Leon ME; Thompson ZJ; Ma Z; Chung CH; Hallanger-Johnson JE; Otto KJ; Rogers KD; Centeno BA; McIver B
Endocr Relat Cancer; 2017 Mar; 24(3):127-136. PubMed ID: 28104680
[TBL] [Abstract][Full Text] [Related]
24. The variable phenotype and low-risk nature of RAS-positive thyroid nodules.
Medici M; Kwong N; Angell TE; Marqusee E; Kim MI; Frates MC; Benson CB; Cibas ES; Barletta JA; Krane JF; Ruan DT; Cho NL; Gawande AA; Moore FD; Alexander EK
BMC Med; 2015 Aug; 13():184. PubMed ID: 26253102
[TBL] [Abstract][Full Text] [Related]
25. Interinstitutional variation in predictive value of the ThyroSeq v2 genomic classifier for cytologically indeterminate thyroid nodules.
Marcadis AR; Valderrabano P; Ho AS; Tepe J; Swartzwelder CE; Byrd S; Sacks WL; Untch BR; Shaha AR; Xu B; Lin O; Ghossein RA; Wong RJ; Marti JL; Morris LGT
Surgery; 2019 Jan; 165(1):17-24. PubMed ID: 30360906
[TBL] [Abstract][Full Text] [Related]
26. Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.
Jug RC; Datto MB; Jiang XS
Cancer Cytopathol; 2018 Jul; 126(7):471-480. PubMed ID: 29637728
[TBL] [Abstract][Full Text] [Related]
27. Ultrasound characterization for thyroid nodules with indeterminate cytology: inter-observer agreement and impact of combining pattern-based and scoring-based classifications in risk stratification.
Lam CA; McGettigan MJ; Thompson ZJ; Khazai L; Chung CH; Centeno BA; McIver B; Valderrabano P
Endocrine; 2019 Nov; 66(2):278-287. PubMed ID: 31300961
[TBL] [Abstract][Full Text] [Related]
28. Histopathology of telomerase reverse transcriptase promoter (
Pinto JO; Livhits MJ; Yeh MW; Kaykov A; Klopper JP; Kloos RT; Alshalalfa M; Hao Y; Huang J; Endo M
J Clin Transl Endocrinol; 2024 Mar; 35():100329. PubMed ID: 38116167
[TBL] [Abstract][Full Text] [Related]
29. Utilities of
Guan H; Toraldo G; Cerda S; Godley FA; Rao SR; McAneny D; Doherty G; Braverman L; Lee SL
Thyroid; 2020 Apr; 30(4):536-547. PubMed ID: 31996097
[No Abstract] [Full Text] [Related]
30. Prognostic Value of Preoperative Molecular Testing and Implications for Initial Surgical Management in Thyroid Nodules Harboring Suspected (Bethesda V) or Known (Bethesda VI) Papillary Thyroid Cancer.
Schumm MA; Shu ML; Hughes EG; Nikiforov YE; Nikiforova MN; Wald AI; Lechner MG; Tseng CH; Sajed DP; Wu JX; Yeh MW; Livhits MJ
JAMA Otolaryngol Head Neck Surg; 2023 Aug; 149(8):735-742. PubMed ID: 37382944
[TBL] [Abstract][Full Text] [Related]
31. Characterization and Clinical Significance of EIF1AX Mutations and Co-Mutations in Cytologically Indeterminate Thyroid Nodules: A 5-Year Retrospective Analysis.
Gargano SM; Badjatia N; Nikolaus Y; Peiper SC; Wang ZX
Acta Med Acad; 2021 Apr; 50(1):4-12. PubMed ID: 34075760
[TBL] [Abstract][Full Text] [Related]
32. Does the likelihood of malignancy in thyroid nodules with RAS mutations increase in direct proportion with the allele frequency percentage?
Hudson TJ; Pusztaszeri MP; Hier MP; Forest VI; Yang JW; Payne RJ
J Otolaryngol Head Neck Surg; 2023 Feb; 52(1):12. PubMed ID: 36774522
[TBL] [Abstract][Full Text] [Related]
33. Repeat Fine-Needle Aspiration With Molecular Analysis in Management of Indeterminate Thyroid Nodules.
Papazian MR; Dublin JC; Patel KN; Oweity T; Jacobson AS; Brandler TC; Givi B
Otolaryngol Head Neck Surg; 2023 Apr; 168(4):738-744. PubMed ID: 35412868
[TBL] [Abstract][Full Text] [Related]
34. Tumor Growth Rate Does Not Predict Malignancy in Surgically Resected Thyroid Nodules Classified as Bethesda Category III with Architectural Atypia.
Kim M; Jeon MJ; Han M; Lee JH; Song DE; Baek JH; Kim TY; Kim WB; Shong YK; Kim WG
Thyroid; 2019 Feb; 29(2):216-221. PubMed ID: 30421654
[TBL] [Abstract][Full Text] [Related]
35. Risk assessment of cytologically indeterminate thyroid nodules with integrated molecular testing and repeat biopsy: a surgical decision-oriented tool.
Guan X; Yu T; Zhang Z; Chen L; Yan A; Li Y; Li J; Wang D; Sun J; Wang F; Miao G
World J Surg Oncol; 2023 Feb; 21(1):34. PubMed ID: 36737779
[TBL] [Abstract][Full Text] [Related]
36. The utility of ThyroSeq
Li W; Justice-Clark T; Cohen MB
Cytopathology; 2021 Jul; 32(4):505-512. PubMed ID: 33914382
[TBL] [Abstract][Full Text] [Related]
37. A five-gene panel refines differential diagnosis of thyroid nodules.
Lu SY; Chen YC; Zhu CF; Chen J; Zhou QY; Zhang MM; Zhang QY; Lu M; Yang L; Wu J; Zhao SX; Song HD; Ye XP
J Clin Lab Anal; 2021 Sep; 35(9):e23920. PubMed ID: 34318534
[TBL] [Abstract][Full Text] [Related]
38. Clinical utility of a microRNA classifier in cytologically indeterminate thyroid nodules with RAS mutations: A multi-institutional study.
Tumati A; Egan CE; Lee-Saxton YJ; Marshall TE; Lee J; Jain K; Heymann JJ; Gokozan H; Azar SA; Schwarz J; Keutgen XM; Laird AM; Beninato T; Zarnegar R; Fahey TJ; Finnerty BM
Surgery; 2024 Jan; 175(1):234-240. PubMed ID: 37907382
[TBL] [Abstract][Full Text] [Related]
39. Preoperative Role of RAS or BRAF K601E in the Guidance of Surgery for Indeterminate Thyroid Nodules.
Ravella L; Lopez J; Descotes F; Giai J; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Decaussin-Petrucci M
World J Surg; 2020 Jul; 44(7):2264-2271. PubMed ID: 32227276
[TBL] [Abstract][Full Text] [Related]
40. [Active surveillance for thyroid micro-malignant nodules].
Huang YC; Huang ZH; Cai HZ; Zhang XW; Yan DG; An CM; Zhang ZM; Niu LJ; Li ZJ
Zhonghua Zhong Liu Za Zhi; 2022 Nov; 44(11):1214-1220. PubMed ID: 36380671
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
